IC51 + HAVRIX
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Japanese Encephalitis
Conditions
Japanese Encephalitis
Trial Timeline
Sep 1, 2005 → Aug 1, 2008
NCT ID
NCT00596271About IC51 + HAVRIX
IC51 + HAVRIX is a phase 3 stage product being developed by Valneva SE for Japanese Encephalitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00596271. Target conditions include Japanese Encephalitis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00596271 | Phase 3 | Completed |
Competing Products
20 competing products in Japanese Encephalitis